Compare TRNO & RYTM Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | TRNO | RYTM |
|---|---|---|
| Founded | 2009 | 2008 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Real Estate | Biotechnology: Pharmaceutical Preparations |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 7.0B | 5.8B |
| IPO Year | 2009 | 2017 |
| Metric | TRNO | RYTM |
|---|---|---|
| Price | $66.06 | $96.30 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 12 | 14 |
| Target Price | $67.83 | ★ $131.14 |
| AVG Volume (30 Days) | 460.2K | ★ 597.1K |
| Earning Date | 05-05-2026 | 05-05-2026 |
| Dividend Yield | ★ 3.21% | N/A |
| EPS Growth | ★ 103.65 | 28.34 |
| EPS | ★ 3.91 | N/A |
| Revenue | ★ $476,383,000.00 | N/A |
| Revenue This Year | $8.42 | $55.34 |
| Revenue Next Year | $9.10 | $86.06 |
| P/E Ratio | $16.60 | ★ N/A |
| Revenue Growth | ★ 24.51 | N/A |
| 52 Week Low | $53.00 | $55.31 |
| 52 Week High | $67.55 | $122.20 |
| Indicator | TRNO | RYTM |
|---|---|---|
| Relative Strength Index (RSI) | 57.74 | 67.31 |
| Support Level | $59.39 | $84.03 |
| Resistance Level | $66.97 | $100.70 |
| Average True Range (ATR) | 1.67 | 4.05 |
| MACD | -0.15 | 1.14 |
| Stochastic Oscillator | 82.19 | 85.99 |
Terreno Realty Corp is a real estate investment trust engaged in acquiring, owning, and operating industrial real estate in six coastal U.S. markets: Los Angeles, Northern New Jersey/New York City, San Francisco Bay Area, Seattle, Miami, and Washington, D.C. The company invests in several types of industrial real estate, including warehouse/distribution, flex (including light industrial and research and development), transshipment, and improved land.
Rhythm Pharmaceuticals Inc is a commercial-stage biopharmaceutical company engaged in the development and commercialization of therapies for patients with rare neuroendocrine diseases. The company is focused on advancing its melanocortin-4 receptor (MC4R) agonists, including its main asset, IMCIVREE (setmelanotide), as a precision medicine designed to treat hyperphagia and severe obesity caused by rare MC4R pathway diseases. In addition, it has two early-stage investigational MC4R agonists in clinical development, RM-718 and bivamelagon, designed not to cause hyperpigmentation. The company is also focused on advancing potential candidates for congenital hyperinsulinism. It currently operates in two business segments: the United States, which generates maximum revenue, and International.